ANVS News and Press, Annovis Bio Inc. From 05/09/24

2024-05-09 15:34:49 ET Annovis Bio ( NYSE: ANVS ) shares traded higher Thursday after the biotech said that initial data from a Phase 3 trial for its lead candidate buntanetap in early Parkinson’s disease is now expected in June.... Read the full article on Seeking Alph...

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its ...

2024-05-02 16:00:35 ET Summary Annovis Bio's pipeline features a single therapeutic drug, Buntanetap, unlikely to showcase efficacy in AD or PD. Topline data of AD phase II/III trial was released in a press release, and featured a small post-hoc sub-population. The stock plumm...

2024-05-02 09:52:32 ET Summary Annovis Bio, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Their pipeline includes Buntanetap/ANVS 402 for AD, PD, and Lewy Body Dementia, as well as ...

2024-05-02 00:19:50 ET Summary Annovis reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and the focus on mild AD patients were not pre-specified, raising concerns. Annovis faces fin...

2024-04-30 13:43:00 ET More on mid-day movers & stocks. Bakkt Holdings, Inc. (BKKT) Q4 2023 Earnings Call Transcript Bakkt Holdings, Inc. 2023 Q4 - Results - Earnings Call Presentation Cemtrex, Inc. (CETX) Q1 2024 Earnings Call Transcript Bakkt announces ...

2024-04-30 10:01:07 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...

A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...

2024-04-30 09:00:04 ET Sumant Kulkarni from Canaccord Genuity issued a price target of $26.00 for ANVS on 2024-04-30 07:34:00. The adjusted price target was set to $26.00. At the time of the announcement, ANVS was trading at $7.28. ANVS currently trades -67.60% versus it...

2024-04-30 08:24:49 ET More on pre-market losers & stocks. Biodexa shares rally 126% on rapamycin licensing deal NewGenIvf signs non-binding term sheet for potential reverse merger with European Wellness Investment Holdings Seeking Alpha’s Quant Rating on ...